Stock ABBV ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-14 pm EDT 		5-day change 1st Jan Change
161.6 USD +0.19% Intraday chart for AbbVie Inc. -0.59% +4.27%
May. 13 AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders MT
May. 09 Medincell: share price rises on resumption of trading CF

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 130,935 189,171 239,371 285,707 273,605 284,799 - -
Enterprise Value (EV) 1 157,739 266,778 306,225 339,749 320,176 338,419 332,091 323,041
P/E ratio 16.8 x 39.4 x 21 x 24.4 x 57 x 31.3 x 24 x 20.2 x
Yield 4.96% 4.52% 3.92% 3.53% 3.87% 3.83% 4.03% 4.2%
Capitalization / Revenue 3.94 x 4.13 x 4.27 x 4.92 x 5.04 x 5.18 x 4.91 x 4.58 x
EV / Revenue 4.74 x 5.83 x 5.46 x 5.85 x 5.89 x 6.16 x 5.73 x 5.2 x
EV / EBITDA 8.89 x 11.8 x 10.6 x 11 x 12.5 x 12.8 x 11.7 x 10.5 x
EV / FCF 12.4 x 15.9 x 13.9 x 14 x 14.5 x 17.7 x 14 x 12.6 x
FCF Yield 8.1% 6.29% 7.18% 7.14% 6.89% 5.64% 7.15% 7.93%
Price to Book -16.1 x 13.7 x 15.5 x 16.6 x 26.5 x 30.2 x 27 x 22.6 x
Nbr of stocks (in thousands) 1,478,821 1,765,474 1,767,880 1,767,880 1,765,537 1,765,868 - -
Reference price 2 88.54 107.2 135.4 161.6 155.0 161.3 161.3 161.3
Announcement Date 2/7/20 2/3/21 2/2/22 2/9/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 33,266 45,784 56,122 58,054 54,318 54,968 58,003 62,155
EBITDA 1 17,747 22,642 29,018 30,961 25,545 26,456 28,305 30,881
EBIT 1 15,730 21,976 28,215 30,183 24,793 25,526 27,498 30,205
Operating Margin 47.29% 48% 50.27% 51.99% 45.64% 46.44% 47.41% 48.6%
Earnings before Tax (EBT) 1 8,426 3,398 12,989 13,477 6,250 12,004 14,298 16,403
Net income 1 7,882 4,616 11,542 11,836 4,863 7,739 10,646 13,023
Net margin 23.69% 10.08% 20.57% 20.39% 8.95% 14.08% 18.35% 20.95%
EPS 2 5.280 2.720 6.450 6.630 2.720 5.146 6.715 7.972
Free Cash Flow 1 12,772 16,790 21,990 24,248 22,062 19,094 23,737 25,612
FCF margin 38.39% 36.67% 39.18% 41.77% 40.62% 34.74% 40.92% 41.21%
FCF Conversion (EBITDA) 71.97% 74.15% 75.78% 78.32% 86.37% 72.17% 83.86% 82.94%
FCF Conversion (Net income) 162.04% 363.73% 190.52% 204.87% 453.67% 246.72% 222.97% 196.67%
Dividend per Share 2 4.390 4.840 5.310 5.710 5.990 6.180 6.492 6.781
Announcement Date 2/7/20 2/3/21 2/2/22 2/9/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 14,886 13,538 14,583 14,812 15,121 12,225 13,865 13,927 14,301 12,310 14,017 14,182 14,706 13,237 14,314
EBITDA 1 7,506 7,156 7,643 8,090 8,072 5,682 6,710 6,706 6,447 - 7,100 6,877 7,049 - -
EBIT 1 7,333 6,958 7,440 7,909 7,876 5,503 6,520 6,510 6,260 5,195 6,880 6,703 6,796 6,659 6,996
Operating Margin 49.26% 51.4% 51.02% 53.4% 52.09% 45.01% 47.02% 46.74% 43.77% 42.2% 49.08% 47.27% 46.21% 50.31% 48.87%
Earnings before Tax (EBT) 1 - - - - - 475 2,610 1,953 1,212 1,755 3,504 3,346 3,397 - -
Net income 1 4,044 4,490 924 3,949 2,473 239 2,024 1,778 822 1,369 2,264 2,053 2,002 1,115 1,400
Net margin 27.17% 33.17% 6.34% 26.66% 16.35% 1.96% 14.6% 12.77% 5.75% 11.12% 16.15% 14.48% 13.62% 8.42% 9.78%
EPS 2 2.260 2.510 0.5100 2.210 1.380 0.1300 1.140 1.000 0.4600 0.7700 1.567 1.362 1.382 0.6200 0.7800
Dividend per Share 2 1.410 1.410 1.410 1.410 1.480 1.480 1.480 1.480 1.550 - 1.548 1.548 1.548 1.605 1.605
Announcement Date 2/2/22 4/29/22 7/29/22 10/28/22 2/9/23 4/27/23 7/27/23 10/27/23 2/2/24 4/26/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 26,804 77,607 66,854 54,042 46,571 53,619 47,292 38,242
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.51 x 3.428 x 2.304 x 1.745 x 1.823 x 2.027 x 1.671 x 1.238 x
Free Cash Flow 1 12,772 16,790 21,990 24,248 22,062 19,094 23,737 25,612
ROE (net income / shareholders' equity) -160% 188% 159% 151% 143% 165% 174% 214%
ROA (Net income/ Total Assets) 10.6% 3.85% 15.3% 17.2% 14.5% 9.36% 10.7% 13.2%
Assets 1 74,234 119,840 75,543 68,651 33,641 82,668 99,812 98,785
Book Value Per Share 2 -5.510 7.830 8.710 9.740 5.840 5.340 5.970 7.120
Cash Flow per Share 2 8.980 10.50 12.80 14.00 12.90 14.60 15.50 13.80
Capex 1 552 798 787 695 777 827 846 876
Capex / Sales 1.66% 1.74% 1.4% 1.2% 1.43% 1.5% 1.46% 1.41%
Announcement Date 2/7/20 2/3/21 2/2/22 2/9/23 2/2/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
161.3 USD
Average target price
181.6 USD
Spread / Average Target
+12.57%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ABBVIE INC. Stock AbbVie Inc.
+4.27% 285B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+31.06% 682B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.35% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.42% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.02% 327B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.53% 240B
NOVARTIS AG Stock Novartis AG
+10.16% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-8.14% 203B
AMGEN INC. Stock Amgen Inc.
+8.12% 165B
PFIZER, INC. Stock Pfizer, Inc.
-1.42% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. Financials AbbVie Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW